Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07102342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Study acronym: NouvNeu001-01
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase changed: Phase 1 → Phase 1/2v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2025 to Jan 12, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2025 to Jan 12, 2026
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.
Trial Details
NCT Number NCT07102342
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Parkinson Disease
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov